文献速递技术与安全神经泌尿生殖MR

钆特酸葡胺的安全性:35年临床应用及超过1.7亿剂量的综述

Safety of Gadoterate Meglumine: A Review of 35 Years of Clinical Use and More Than 170 Million Doses.
PubMed 文献 · Invest Radiol · 2025-11-01

本综述检索截至2024年12月31日的Embase与PubMed文献,纳入62篇报告钆特酸葡胺安全性结果的出版物,覆盖数周至103岁及各期肾功能不全患者。过敏反应发生率<0.01%至0.58%,至今无确认的无混杂因素肾源性系统性纤维化病例;药物警戒监测显示每10万暴露患者中8例不良反应,最常见为荨麻疹、恶心和呕吐(各0.001%)。结论认为钆特酸葡胺是适用于所有年龄组及肾功能不全患者的安全磁共振成像对比剂。

要点

  • 过敏反应发生率在17项研究中为<0.01%至0.58%,药物警戒监测中过敏反应发生率<0.00035%。
  • 9项研究分析肾源性系统性纤维化,至今无确认的无混杂因素病例与钆特酸葡胺使用相关。
  • 17项研究显示深部脑信号强度无显著增高(最多53次暴露),4项研究显示特定亚组重复暴露后信号强度有所增高但无临床症状。

核心结论

  • 已发表数据与药物警戒监测的临床证据表明,钆特酸葡胺是适用于所有年龄组、多种全身获批适应症(包括肾功能不全患者)的安全磁共振成像对比剂。

研究设计与样本

  • 综述,检索Embase与PubMed截至2024年12月31日的文献,共纳入62篇报告钆特酸葡胺安全性结果的出版物,患者年龄从数周至103岁,包括各期肾功能不全患者。

诊断标准与关键数值

  • 过敏反应发生率在17项研究中报告为<0.01%至0.58%。
  • 药物警戒监测显示每10万暴露患者中8例不良反应,最常见为荨麻疹、恶心和呕吐(各0.001%),过敏反应发生率<0.00035%。
  • 肾源性系统性纤维化在9项研究中分析,至今无确认的无混杂因素病例与钆特酸葡胺使用相关;药物警戒监测未收到无混杂因素的肾源性系统性纤维化报告。
  • 17项研究显示最多53次暴露后深部脑信号强度无显著增高;4项研究显示特定亚组重复暴露后信号强度有所增高但无临床症状。
  • 8项研究描述了与钆暴露相关的症状,但未确立与钆沉积的因果关系。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: The aim of this review was to evaluate the safety profile of gadoterate meglumine from published literature and pharmacovigilance reports of adverse drug reactions (ADRs) encompassing 35 years of clinical use and more than 170 million administered doses.

MATERIALS AND METHODS: A review of published literature up to December 31, 2024 was performed through a search in Embase and PubMed databases. The analysis focused on current safety concerns associated with gadolinium-based contrast agents, the hypersensitivity reactions (HSRs), nephrogenic systemic fibrosis (NSF), gadolinium accumulation, and symptoms associated with gadolinium exposure.

RESULTS: A total of 62 publications reporting safety results for gadoterate meglumine were included. Age ranged from a few weeks to 103 years, including patients with all stages of renal impairment. The incidence of HSRs was reported in 17 studies and ranged from <0.01% to 0.58%. Occurrence of NSF was analyzed in 9 studies; to date, no confirmed unconfounded case of NSF diagnosis has been associated with gadoterate meglumine use. Regarding gadolinium presence in the body, 17 studies did not show any significant signal intensity increase in the deep brain in patients after up to 53 exposures, while 4 showed some signal intensity increase in specific subgroups after repeated exposure, but without any clinical symptoms. Symptoms associated with gadolinium exposure have been described in 8 studies, although no causal relationship with gadolinium deposition was established. Safety data obtained from pharmacovigilance monitoring showed an incidence of adverse reactions in 8 cases per 100,000 patients exposed. The most frequently reported adverse reactions were urticaria, nausea, and vomiting (0.001% each), while the incidence of HSRs was less than 0.00035%. No unconfounded NSF reports were received.

CONCLUSIONS: Clinical evidence from the published data and pharmacovigilance monitoring demonstrated that gadoterate meglumine is a safe magnetic resonance imaging contrast agent for all age groups in a variety of approved indications throughout the whole body, including in patients with renal impairment.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Shahid I, Morvan J, Darmon-Kern E, et al. Safety of Gadoterate Meglumine: A Review of 35 Years of Clinical Use and More Than 170 Million Doses. Invest Radiol. 2025. PMID: 40300199. doi:10.1097/RLI.0000000000001200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。